Since selective pharmacologic targeting of elements of the MAPK pathway has shown promise in the battle against cancer, it is of great interest to identify possible implications of MAPK and especially RAS-RAF-MEK-ERK signaling interference in specific immune cell types. The gene discussed is MAP2K7; the disease is cancer.